Eiger Biopharmaceuticals Inc (EIGR)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
The company reported a superb rise, amid the fiscal time-frame ending March 31 2023
Eiger Biopharmaceuticals Inc reported first quarter of 2023 operating shortfall of $-22.263 million
Published 2023-05-14T07:26:56+00:00
Goran Soko / CSIMarket.com Contributer
![pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
For the most recent fiscal period Eiger Biopharmaceuticals Inc lost money of $-0.52 per share compare to $-0.64 a year before and advanced deficit from $-0.46 per share from the preceding reporting period. The revenue grew strongly by 54.059 % to $4.12 million from $2.67 million in the same reporting period a year before and sequentially revenue surged by 52.745 % from $2.70 million.
For the most recent fiscal period Eiger Biopharmaceuticals Inc realized net deficit of $-22.784 million, larger than $-22.643 million a year ago.
Eiger Biopharmaceuticals Inc is expected to report next financial recent numbers on August 03, 2023.